Tariq Shah1, Balaji Krishnamachary1, Flonne Wildes1, Jannie Wijnen2, Kristine Glunde1, and Zaver M Bhujwalla1
In
understanding the aberrant choline metabolism of cancer, significant effort has
been focused on phosphocholine (PC) but the
role of phosphoethanolamine (PE) is relatively underexplored, even though
tumors show increased PE as consistently as increased PC. Our previous findings in breast cancer cells have
led us to expand our study to understand the role of ethanolamine kinase-1 (EtnK-1)
and PE in pancreatic cell lines. We have
demonstrated that EtnK-1 is the major contributor to PE levels in these cells and
may be a potential therapeutic target.